| Group of drugs | Examples | Possible mechanism of pruritus | Frequency of pruritus |
| Anti-arrhythmic drugs | Amiodarone | Cholestatic liver injury | Case reports |
| Antibiotics | Penicillins | Secondary to skin lesions or cholestatic liver injury | 2 to 20% |
| Cephalosporins | Unknown or secondary to skin lesions | <2% | |
| Macrolides | Secondary to skin lesions or cholestatic liver injury | <0.3% | |
| Carbapenemes | Cholestatic liver injury | Rare | |
| Monobactams | Secondary to skin lesions | Rare | |
| Quinolones | Unknown or secondary to skin lesions | 1 to 4% | |
| Tetracyclines | Unknown or cholestatic liver injury | 1 to 2% | |
| Lincosamides | Secondary to skin lesions or cholestatic liver injury | Rare | |
| Streptogramins | Secondary to skin lesions | 2.5% | |
| Metronidazole | Unknown or secondary to skin lesions | <5% | |
| Rifampin | Unknown | Case report | |
| Tiamphenicol | Unknown | <0.1% | |
| Trimethoprim/sulphamethoxazole | Secondary to skin lesions | 2 to 10% | |
| Cholestatic liver injury | Rare | ||
| Antimalarials | Unknown, but genetic background is important; release of histamine or activation of mu-receptors were postulated | Up to 60 to 70% of Black Africans, uncommon in Caucasians or Asians | |
| Anticoagulants | Ticlopidine | Cholestatic liver injury | Case reports |
| Fractionated heparins | Urticarial reaction | Case reports | |
| Anti-diabetic drugs | Biguanides | Cholestatic liver injury | Case reports |
| Sulphonylurea derivates | Unknown | <5% | |
| Anti-epileptics | Carbamazepine, fosphenytoin, oxcarbazepine, phenytoin, topiramate | Secondary to skin lesions, allergic reaction | Rare |
| Antihypertensive drugs | Angiotensin-converting enzyme inhibitors | Increase of bradykinin level or cholestatic liver injury or secondary to skin lesions | 1 to 15% |
| Angiotensin II antagonists (sartans) | Cholestatic liver injury | Case reports | |
| Beta-adrenergic blockers | Secondary to skin lesions | Frequent, if administered transdermally | |
| Cholestatic liver injury | Rare | ||
| Calcium channel blockers | Secondary to skin lesions or unknown | <2% | |
| Cholestatic liver injury | Case reports | ||
| Methyldopa | Unknown or secondary to skin lesions | <2% | |
| Sildenafil | Cholestatic liver injury | Case report | |
| BRAF inhibitors | Vemurafenib | Unknown | 19% |
| Cytokines, growth factors and monoclonal antibodies | Granulocyte-macrophage colony-stimulating factor | Unknown | Common |
| Interleukin 2 | Direct pruritogenic effect of interleukin 2 | Very common | |
| Matuzumab | Unknown | <10% | |
| Lapatinib | Unknown or urticarial reaction | 3% | |
| Cytostatics | Chlorambucil | Secondary to skin lesions | Case reports |
| Paclitaxel | Unknown or secondary to skin lesions | 10 to 14% | |
| Tamoxifen | Sebostasis/xerosis | 3 to 5% | |
| Epidermal growth factor inhibitors | Cetuximab | Unknown | 22% |
| Erlotinib | Unknown | 18% | |
| Panitumumab | Unknown | 58% | |
| Hypolipaemic drugs | Statins | Unknown or secondary to skin lesions | 16% |
| Monoclonal antibody to CTLA-4 | Ipilimumab | Unknown | 31% |
| Plasma volume expanders | Hydroxyethyl starch (HES) | Deposition of HES in small peripheral nerves or in Schwann's cells of cutaneous nerves | 12.6 to 54% |
| Psychotropic drugs | Tricyclic antidepressants | Cholestatic liver injury | Rare |
| Selective serotonin re-uptake inhibitors | Activation of peripheral serotonin receptors or secondary to skin lesions | Rare | |
| Neuroleptics | Cholestatic liver injury | Rare | |
| Others | Anti-thyroid agents | Cholestatic liver injury | Rare |
| Nonsteroidal antiinflammatory drugs | Increased synthesis of leukotrienes | 1 to 7% | |
| Cholestatic liver injury | Rare | ||
| Corticosteroids | Cholestatic liver injury | Very rare | |
| Sex hormones | Cholestatic liver injury | Rare | |
| Opioids | Centrally mediated process via mu-opioid receptor | 2 to 100% | |
| Inhibitors of xanthine oxidase | Secondary to skin lesions | 0.8 to 2.1% |